ClinicalTrials.gg
RecruitingNCT07092878Updated Jul 30, 2025

Effects of Chamomile With L-theanine Beverage Among Young Women Experiencing Primary Dysmenorrhea

An interventional study of Chamomile (Matricaria recutita) and Chamomile in Primary Dysmenorrhea, sponsored by Universiti Tunku Abdul Rahman. Recruiting at 1 site in Malaysia. Open to female participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Universiti Tunku Abdul Rahman · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Female
01

Study summary

This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.

Read the detailed description

This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.

02

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • primary dysmenorrhea
  • sleep
  • mood
03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

This study's planned enrollment of 30 is below the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Universiti Tunku Abdul Rahman is the lead sponsor of 37 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A VAS score of ≥4 cm for the past three consecutive menstrual cycles
  • Regular monthly menstruation
  • No history of allergies or psychological/gynecological illnesses
  • Absence of secondary dysmenorrhea
  • No current use of any medications
  • No ongoing non-pharmacological management for dysmenorrhea.

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CTT

    Participants in the intervention group will consume a chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.

    Dietary Supplement: Chamomile (Matricaria recutita)

  • Placebo comparator
    Non-CTT

    Participants in the control group will consume a chamomile-flavored beverage (non-CTT), which is flavored with commercial chamomile flavoring.

    Dietary Supplement: Chamomile

Interventions

  • Dietary supplementMatricaria recutitaStudies of Matricaria recutitaMatricaria recutita pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.

  • Dietary supplementChamomile

    A chamomile-flavored beverage

    Also known as: Chamomile flavored beverage

06

What researchers measure

Primary outcomes

  1. Pain intensity

    The pain intensity is assessed using the Visual Analogue Scale (VAS) and the Numeric Rating Scale (NRS). Participants mark the point on the scale (0 to 10) that best represents the average intensity of their menstrual pain. A higher score on the VAS and NRS indicates greater pain intensity.

    Time frame: 2 months

  2. Menstrual symptoms

    The Cox Menstrual Symptom Scale (CMSS) is used to assess the severity of menstrual-related symptoms experienced by participants during their most recent menstrual cycle. Each item in the CMSS is rated on a scale from 0 (not noticeable), 1 (slightly bothersome), 2 (moderately bothersome), 3 (severely bothersome), to 4 (very severely bothersome).

    Time frame: 2 months

  3. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) is used to assess the sleep quality of participants during the past week. The total PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: 2 months

  4. Mood

    The Profile of Mood States (POMS) is used to assess six mood subscales (vigor, tension, depression, anger, fatigue, and confusion) of participants during the past week. Each item is rated on a 5-point Likert scale, ranging from 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a lot), and 4 (extremely).

    Time frame: 2 months

Secondary outcomes

  1. Hemoglobin

    Hemoglobin is measured in mmol/L

    Time frame: 2 months

07

Study locations

1 of 1 sites recruiting
  • UTAR
    Kampar, Perak 31900, Malaysia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This project is financially supported by a beverage company and may contain commercially sensitive data. If other researchers require the IPD, they must obtain approval from the beverage company through the principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2025, 4 months after the start.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2025
First posted
Jul 30, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Jul 31, 2025
CompletionEst.
Jul 31, 2025
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07092878
Lead sponsor
Universiti Tunku Abdul Rahman
Responsible party
Tan Chin Xuan (Assistant Professor, Universiti Tunku Abdul Rahman) — Principal investigator
First posted
Jul 30, 2025
Start date
Mar 1, 2025
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Jul 30, 2025

Study contacts

Chin Xuan Tan, PhD
Contact
tancx@utar.edu.my
+605-4688888 ext. 4529

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Matricaria recutita

Start the discussion